Clinical Trial

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Study acronym: Umbriel
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Protocol Amendment History 2 changes
notable Trial sites expanded: 213 -> 221 locations 2026-07-21
notable Trial sites expanded: 209 -> 213 locations 2026-05-30
Trial Details
NCT Number NCT06932263
Lead Sponsor AstraZeneca
Conditions Asthma
Enrollment 540 participants
Start Date 2025-03-26
Primary Completion 2027-06-07 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-20